Thursday - March 26, 2026
FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
March 25, 2026
WASHINGTON, March 25 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following news release:

* * *

FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome

*

The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).

"Today is a milestone day for children . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products